Cancer treatment Cancer cases have disturbingly increased in the recent times.An estimated 100,000 new cases of cancer are reported every year.
The exact number of cases may be much higher than this figure as many cases remain undetected or unreported...
Clavis Pharma ASA Announces Promising Results for Oral CP-4126 --Clavis Pharma announced today that pre-clinical studies have demonstrated that Oral CP-4126 acts as a very efficient pro-drug for gemcitabine (Gemzar). Oral CP-4126 is a Lipid Vector Technology (LVT) derivative that can be given as...
FDA delays decision on Eli Lilly blood clot drug prasugrel by 3 months, few surprised a day after the company announced the Food and Drug Administration needed three more months to review its blood thinner drug.The FDA did not ask for new clinical trials, but company spokeswoman Tammy Hull would not go into details about...
FDA delays decision on Eli Lilly blood clot drug prasugrel by 3 months, few surprised a day after the company announced the Food and Drug Administration needed three more months to review its blood thinner drug.The FDA did not ask for new clinical trials, but company spokeswoman Tammy Hull would not go into details about...
Combination Gemcitabine and Radiation Modestly Improves Survival in Pancreatic Cancer June 17, 2008 (Chicago, Illinois) Gemcitabine (Gemzar) combined with radiotherapy is associated with a small survival benefit over gemcitabine alone for localized unresectable pancreatic cancer, researchers reported here at the...
Lovells scoops patent court regular Eli Lilly on three cases Lovells has scored its first UK patent litigation instructions from US pharmaceutical company Eli Lilly, scooping the lead role on three disputes set to hit the courts in 2009.Eli Lilly has chosen Lovells to defend it against generic drug...
Gemzar Improves Survival with Early Pancreatic Cancer _ Gemzar Improves Survival with Early Pancreatic Cancer.
Combination treatment safe for pancreatic cancer - Treating pancreatic cancer with a combination of treatments prior to surgery is safe and may be beneficial for patients, according to a new study.Led by by Dr.
James Moser of the University of Pittsburgh Cancer Institute (UPCI)...
Lilly drug doubles pancreatic cancer survival: study CHICAGO (Reuters) - Eli Lilly and Co's chemotherapy drug Gemzar more than doubled the overall survival for early stage pancreatic cancer patients five years after surgery to remove their tumors, according to results from a long-term...
One Step Closer To Tailored Treatment For Lung Cancer Current Article Ratings: Patient / Public: Health Professional: Article Opinions: 0 posts A major study released in the Journal of Clinical Oncology has shown that doctors could increase the survival of patients with a specific type of lung...
Gemzar Helps Fight Pancreatic Cancer (Chicago) -- For some patients who undergo surgery for pancreatic cancer, taking the cancer drug Gemzar afterward more than doubles the chance of survival, researchers report.The bad news: In up to 80% of patients, symptoms of...
MethylGene Reports Clinical Data From Phase II Study Evaluating MGCD0103 In Relapsed Or Refractory Non-Hodgkin MethylGene Inc.recently announced preliminary data from a Phase II clinical study evaluating MGCD0103, a novel, isoform-selective histone deacetylase (HDAC) inhibitor, in relapsed or refractory non-Hodgkin lymphomas (Trial 008).
Results...
MethylGene to Present at the 7th Annual Needham Biotechnology & Medical Technology Conference MethylGene Inc.(TSX: MYG) is a publicly-traded, clinical stage, biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer.
The Company's lead product, MGCD0103, is an oral,...
MethylGene Inc.: MethylGene to Present at the 7th Annual Needham Biotechnology & Medical Technology Conference - MethylGene Inc.(TSX:MYG) today announced that Mr.
Donald F.
Corcoran, President and Chief Executive Officer, will present an overview of the Company at the 7th Annual Needham Biotechnology and Medical Technology Conference in New...
MethylGene to Present at the 7th Annual Needham Biotechnology & Medical Technology Conference MONTREAL, QUEBEC -- (MARKET WIRE) -- 06/05/08 -- MethylGene Inc.(TSX:MYG) today announced that Mr.
Donald F.
Corcoran, President and Chief Executive Officer, will present an overview of the Company at the 7th Annual Needham...
MethylGene to Present at the 7th Annual Needham Biotechnology & Medical Technology Conference -- MethylGene Inc.(Toronto:MYG.TO - News) today announced that Mr.
Donald F.
Corcoran, President and Chief Executive Officer, will present an overview of the Company at the 7th Annual Needham Biotechnology and Medical Technology...
MethylGene to Present at the 7th Annual Needham Biotechnology & Medical Technology Conference -- MethylGene Inc.(TSX: MYG) today announced that Mr.
Donald F.
Corcoran, President and Chief Executive Officer, will present an overview of the Company at the 7th Annual Needham Biotechnology and Medical Technology Conference in New...
MethylGene to Present at the 7th Annual Needham Biotechnology & Medical Technology Conference - MethylGene Inc.(TSX:MYG) today announced that Mr.
Donald F.
Corcoran, President and Chief Executive Officer, will present an overview of the Company at the 7th Annual Needham Biotechnology and Medical Technology Conference in New...
ASCO: Chemoradiation Confers Survival Edge in Advanced Pancreatic Cancer CHICAGO, June 4 -- For locally advanced unresectable pancreatic cancer, chemoradiation may add a few weeks of survival compared with chemotherapy alone, according to a small randomized trial.Radiotherapy plus gemcitabine (Gemzar) ...
Eli Lilly upgraded to outperform at Cowen & Co. on Effient approval odds in U.S. [XFNA] BOSTON (Thomson Financial) - Eli Lilly & Co.was upgraded Wednesday to outperform from neutral by Cowen & Co., which said the stock's performance is predominantly keyed to the U.S.
approval of the company's anti-clotting...
Report states drug is helping more survive pancreatic cancer A chemotherapy drug called Gemzar doubles the number of pancreatic cancer patients who survive five years after surgery, a new study shows.In a study of 368 patients who had surgery to remove their pancreas, 21 percent of those...
Study: Chemotherapy Drug Doubles Pancreatic Cancer Survival Rate A chemotherapy drug called Gemzar doubles the number of pancreatic cancer patients who survive five years after surgery, a study shows.In a study of 368 patients who had surgery to remove their pancreas, 21% of those treated with ...
New Hope for Tough-to-Treat Cancers SATURDAY, May 31 (HealthDay News) Patients diagnosed with pancreatic cancer which historically carries a grim prognosis nearly doubled their overall survival when the cancer drug Gemzar was used after surgery, new research shows.
Lilly drug doubles pancreatic cancer survival: study -0400 (Reuters Health) By Susan Kelly CHICAGO (Reuters) - Eli Lilly and Co's chemotherapy drug Gemzar more than doubled the overall survival for early stage pancreatic cancer patients five years after surgery to remove their tumors,...
Advances In Cancer Treatment And Quality Of Life New studies evaluating the latest treatments and quality-of-life improvements for cancer patients were presented at a press briefing of the 44th Annual Meeting of the (ASCO).'These studies identify promising new treatments for patients...
